Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC On track to report topline pivotal data for neladalkib in TKI pre-treated advanced ALK-positive NSCLC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback